drugset / Trial / NCT07313670

Outcome of Using Hydrocortisone in Early Treatment of Pediatric Septic Shock

NCT07313670

Completed 122 enrolled Muhammad Aamir Latif
RandomizedParallel-groupOpen-labelTreatment

Summary

Although, hydrocortisone has shown promise in managing refractory shock, its role in early septic shock management remains unclear. This study aims to provide robust evidence on the clinical and hemodynamic outcomes of early hydrocortisone use in pediatric septic shock, contributing to standardized treatment protocols and improved survival rates.

Timeline

Start
2025-07-01
Primary completion
2025-12-30
Completion
2025-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrocortisone Other / unclassified 2 mg/kg Intravenous